The FDA using artificial intelligence to fast-track drug approvals is grabbing headlines and igniting heated debate. In a new JAMA article, top FDA officials unveiled plans to overhaul how new drugs and devices get the green light. The goal? Radically increase efficiency and deliver treatments faster.
But while the FDA says this will benefit patients especially those with rare or neglected diseases experts warn the agency may be moving too fast.
Here are four important points from the article:
- The FDA is adopting artificial intelligence to speed up drug and device approval processes, aiming to reduce review times to weeks.
- The agency launched an AI tool called Elsa to assist in reviewing drug applications and inspecting facilities.
- Critics are concerned about AI inaccuracies and the potential erosion of safety standards.
- The FDA is also targeting harmful food additives and dyes banned in other countries to improve public health.
Table of contents
Operation Warp Speed: The New Normal?
According to FDA Commissioner Dr. Marty Makary and vaccine division chief Dr. Vinay Prasad, the pandemic showed that rapid reviews are possible. They want to replicate that success, sometimes requiring just one major clinical study for drug approval instead of two.
This FDA artificial intelligence plan builds on what worked during Operation Warp Speed but critics say it might ignore vital safety steps.
Meet Elsa: The FDA’s New AI Assistant
Last week, the FDA introduced Elsa, a large-language AI model similar to ChatGPT. Elsa can help inspect drug facilities, summarize side effects, and scan huge datasets up to 500,000 pages per application.
Sounds impressive, right? Not everyone agrees.
Employees say Elsa sometimes hallucinates and spits out inaccurate results. Worse, it still needs heavy oversight. For now, it’s not a time-saver it’s a trial run.
Critics Raise the Alarm
While the FDA drug review AI tool is promising, former health advisors remain skeptical. “I’m not seeing the beef yet,” said Stephen Holland, a former adviser on the House Energy and Commerce Committee.
The FDA’s workforce has also shrunk from 10,000 to 8,000. That’s nearly 2,000 fewer staff trying to manage ambitious reforms.
Food Oversight and Chemical Concerns
The agency isn’t stopping at drugs. The new roadmap also targets U.S. food ingredients banned in other countries. The goal? Healthier meals for children and fewer artificial additives. The FDA has already started urging companies to ditch synthetic dyes.
Drs. Makary and Prasad stress the need to re-evaluate every additive’s benefit-to-harm ratio, part of a broader push to reduce America’s “chemically manipulated diet.”
Ties to Industry Spark Distrust
Despite calls for transparency, the FDA’s six-city, closed-door tour with pharma CEOs raised eyebrows. Critics, including Dr. Reshma Ramachandran from Yale, say it blurs the line between partnership and favoritism.
She warns this agenda reads “straight out of PhRMA’s playbook,” referencing the drug industry’s top trade group.
Will AI Save or Sabotage Public Trust?
Supporters say the FDA using artificial intelligence could cut red tape and get life-saving treatments to market faster. Opponents fear it’s cutting corners.
One thing is clear: This bold AI experiment will shape the future of medicine for better or worse.
| Latest From Us
- Forget Towers: Verizon and AST SpaceMobile Are Launching Cellular Service From Space

- This $1,600 Graphics Card Can Now Run $30,000 AI Models, Thanks to Huawei

- The Global AI Safety Train Leaves the Station: Is the U.S. Already Too Late?

- The AI Breakthrough That Solves Sparse Data: Meet the Interpolating Neural Network

- The AI Advantage: Why Defenders Must Adopt Claude to Secure Digital Infrastructure


